ADVICE ABOUT REPORTING

- Report adverse experiences with medications
- Report Serious adverse events. An event is serious when the patient outcome is:
 - death
 - life-threatening (real risk of dying)
 - hospitalization (initial or prolonged)
 - disability (significant, persistent or permanent)
 - congenital anomaly
 - required intervention to prevent permanent impairment or damage

• Report even if:

- you're not certain the product caused adverse event
- you don't have all the details although point nos. 1, 5, 8, 11, 20 & 22 (see reverse) are essentially required.

Who can report:

 any health care professional (Doctors including Dentists, Nurses, and Pharmacists).

• Where to report:

- after completing, please return this form to the same Pharmacovigilance Centre from where you received.
- a list of country vide Pharmacovigilance Centres is available at www.cdsco.nic.in.
- in any case of doubt, you may send this form to the National Pharmacovigilance Centre at: Central Drugs Standard Control Organisation, Directorate General of Health Services, Ministry of Health & Family Welfare, Nirman Bhawan, New Delhi 110 011.

What happens to the submitted information submitted:

- the information provided in this form is handled in strict confidence. Peripheral Pharmacovigilance will forward this form to the Regional Pharmacovigilance Centres, where the causality analysis is carried out and the information is forwarded to the Zonal Pharmacovigilance Centres. Finally the data is statistically analysed and forwarded to the global Pharmacovigilance Database managed by WHO Uppsala Monitoring Center in Sweden.
- the data is periodically reviewed by the National Pharmacovigilance Advisory Committee constituted by the Ministry of Health and Family Welfare. The Committee is entrusted with responsibility to review the data and suggest any interventions that may be required.

Adverse Drug Event Reporting Form

For VOLUNTARY reporting of adverse drug events by health care professionals





Central Drugs Standard Control Organisation Directorate General of Health Services,

Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Nirman Bhawan, New Delhi 110011 WWW.cdsco.nic.in

ATTENTION HEALTH CARE PROFESSIONALS YOUR Can Help Us Ensure Medications



Central Drugs Standard Control Organisation Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, Nirman Bhawan, New Delhi 110 011

www.cdsco.nic.in

Adverse Drug Event Reporting Form

A. Patient in	formation			
Patient identifier initials First less)	2. Age at time of event:		3. Sex	F M
(First, last) ————— Date of birth:	Or (dd/mm/yy)		4. Weight	kgs
B. Suspecte	d Adverse Ev	/ent		
D. Suspecte	a Auverse L	verit		
5. Outcomes attribu		disab	ility	
(check all that ap	piy)		enital anomaly	
death	(dd/mm/yy)		red intervention	to prevent
		anent impairment/damage		
hospitalization	— initial or prolonged			
6. Datesof event sta	arting (dd/mm/yy)	7. Dates of	event stopping	(dd/mm/yy)
8. Describe event o	r problem			
9. Relevant tests/lab	ooratory data, includi	ng dates		
10. Other relevant his (e.g., allergies, race, pr	story, including pre-e regnancy, smoking and	xisting medi alcohol use, ł	cal conditions nepatic/renal dys	function, etc.)

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to & will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the event.

For VOLUNTARY reporting of Adverse Drug Events by health care professionals

Report

To filled in by Pharmacovigillance centres receiving the form

C. Sus	spect medic	cation(s)		
11. Name	(Brand and/or		eled Strength)	(Manufacturer)
gen #1	neric name)			
#2				
π2				
12. Dose	Eroguonov	Route used	12 Thorony dates (if	unknown, give duration)
#1	Frequency	noute useu	From	To
# I				
#2			(dd/mm/yy) #2	(dd/mm/yy)
14. Diagnosis	for use (separate indi	cations with comma	as) 15. Event a	bated after use
#1				d or dose reduced
			#1 yes	no Not Applicable
#2			#2 yes [no Not Applicable
	``		17 Event re	
16. Lot # (if known) Exp. date (if known) #1 #1		reintroc	17. Event reappeared after reintroduction	
			#1 yes	no
#2	#2		#2 yes	no Not
			rapy dates including	☐ ^{no} ☐ Applicable
	nician (if no and Professiona		orter)	
	and Professiona	I Address: _	orter)	
19. Name	and Professiona	I Address: _	_ Pin code:	
19. Name	and Professiona	I Address: _		
Tel No With s	and Professiona	I Address: _	Pin code: y:	
Tel No With s	o.:STD code	Speciality	_ Pin code:	
19. Name Tel No With:	o.:STD code	Speciality	_Pin code: y: tiality section	
19. Name Tel No With:	o.:STD code	Speciality	_Pin code: y: tiality section	
Tel No With:	o.:STD code Oorter (see)	Speciality	_Pin code: y: tiality section	
Tel No With: E. Rep 20. Name &	and Professiona o.: STD code Oorter (See of Address:	Speciality Confiden Pr	_ Pin code: y: tiality section none#	n below)
Tel No With: E. Rep 20. Name &	and Professiona o.: STD code oorter (see	Speciality	_ Pin code: y: tiality section none#	n below)
Tel No. With: E. Rep 20. Name &	and Professiona o.: STD code oorter (see of the second sec	Speciality Confiden Pr	Pin code: y: tiality section one#	n below)
Tel No. With: E. Rep 20. Name &	and Professiona o.: STD code oorter (see	Speciality Confiden Pr (yy) 23. Occup dentity disclo	Pin code: y: tiality section one#	n below) 24. Also reported to no one else